Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Garzotto

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Anti-Cancer Drugs|September 27, 2016
Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlatesColin P Bergstrom, Brian Ruffell, Christine M T Ho, et al.
Cancer Causes & Control : CCC|November 1, 2019
Polymorphisms in oxidative stress pathway genes and prostate cancer riskZhenzhen Zhang, Duo Jiang, Chi Wang, et al.
Urology|May 8, 2007
Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsyStephen E F Spurgeon, Solange Mongoue-Tchokote, Lauren Collins, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomyTomasz M Beer, Anne Myrthue, Mark Garzotto, et al.
The Prostate|October 30, 2009
CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicityDavid Z Qian, Brooks L S Rademacher, Janet Pittsenbarger, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2006
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancerTomasz M Beer, Milind M Javle, Christopher W Ryan, et al.
Urology|April 15, 2008
Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancerBruce Montgomery, Philip Lavori, Mark Garzotto, et al.
Cancer Research|April 15, 2010
ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21Hao Geng, Brooks L Rademacher, Janet Pittsenbarger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
Prostate cancer-associated gene expression alterations determined from needle biopsiesDavid Z Qian, Chung-Ying Huang, Catherine A O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2013
Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancerChristine M Barnett, Michael C Heinrich, Jeong Lim, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Anti-Cancer Drugs|September 27, 2016
Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlatesColin P Bergstrom, Brian Ruffell, Christine M T Ho, et al.
Cancer Causes & Control : CCC|November 1, 2019
Polymorphisms in oxidative stress pathway genes and prostate cancer riskZhenzhen Zhang, Duo Jiang, Chi Wang, et al.
Urology|May 8, 2007
Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsyStephen E F Spurgeon, Solange Mongoue-Tchokote, Lauren Collins, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomyTomasz M Beer, Anne Myrthue, Mark Garzotto, et al.
The Prostate|October 30, 2009
CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicityDavid Z Qian, Brooks L S Rademacher, Janet Pittsenbarger, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2006
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancerTomasz M Beer, Milind M Javle, Christopher W Ryan, et al.
Urology|April 15, 2008
Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancerBruce Montgomery, Philip Lavori, Mark Garzotto, et al.
Cancer Research|April 15, 2010
ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21Hao Geng, Brooks L Rademacher, Janet Pittsenbarger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
Prostate cancer-associated gene expression alterations determined from needle biopsiesDavid Z Qian, Chung-Ying Huang, Catherine A O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2013
Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancerChristine M Barnett, Michael C Heinrich, Jeong Lim, et al.
Pageof 8